Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology
Orexo AB (STO: ORX, OTCQX: ORXOY) has entered into a collaboration with Abera Bioscience to develop nasal powder vaccines using Orexo's AmorphOX® technology. The partnership aims to develop mucosal vaccines, initially focusing on Abera's influenza vaccine candidate. The AmorphOX technology has demonstrated potential to improve stability and efficacy of various active ingredients, from small molecules to larger biomolecules like vaccines.
The collaboration is funded through Abera's previously received grants, primarily from CEPI (Coalition for Epidemic Preparedness Innovation). The partnership represents a strategic step in leveraging AmorphOX's scalability, combining Orexo's powder formulation expertise with Abera's 30+ years of vaccine development experience.
Orexo AB (STO: ORX, OTCQX: ORXOY) ha avviato una collaborazione con Abera Bioscience per sviluppare vaccini in polvere nasale utilizzando la tecnologia AmorphOX® di Orexo. L'obiettivo della partnership è sviluppare vaccini mucosali, concentrandosi inizialmente sul candidato vaccinale contro l'influenza di Abera. La tecnologia AmorphOX ha dimostrato potenziale per migliorare la stabilità e l'efficacia di vari principi attivi, da piccole molecole a biomolecole più grandi come i vaccini.
La collaborazione è finanziata attraverso i finanziamenti precedentemente ricevuti da Abera, principalmente da CEPI (Coalizione per l'Innovazione nella Preparazione agli Epidemie). Questo accordo rappresenta un passo strategico per sfruttare la scalabilità di AmorphOX, combinando l'expertise nella formulazione in polvere di Orexo con oltre 30 anni di esperienza di sviluppo vaccinale di Abera.
Orexo AB (STO: ORX, OTCQX: ORXOY) ha entrado en una colaboración con Abera Bioscience para desarrollar vacunas en polvo nasal utilizando la tecnología AmorphOX® de Orexo. La asociación tiene como objetivo desarrollar vacunas mucosales, centrándose inicialmente en el candidato a vacuna contra la influenza de Abera. La tecnología AmorphOX ha demostrado potencial para mejorar la estabilidad y la eficacia de varios ingredientes activos, desde moléculas pequeñas hasta biomoléculas más grandes como las vacunas.
La colaboración está financiada a través de las subvenciones que Abera ha recibido previamente, principalmente de CEPI (Coalición para la Innovación en la Preparación para Epidemias). La asociación representa un paso estratégico para aprovechar la escalabilidad de AmorphOX, combinando la experiencia en formulaciones en polvo de Orexo con más de 30 años de experiencia en desarrollo de vacunas de Abera.
Orexo AB (STO: ORX, OTCQX: ORXOY)는 Abera Bioscience와 협력하여 Orexo의 AmorphOX® 기술을 사용한 비강 분말 백신을 개발하기로 했습니다. 이번 파트너십은 Abera의 인플루엔자 백신 후보에 초기 초점을 맞춰 점막 백신을 개발하는 것을 목표로 합니다. AmorphOX 기술은 작은 분자에서부터 백신과 같은 큰 바이오 분자에 이르기까지 다양한 활성 성분의 안정성과 효능을 향상시킬 수 있는 잠재력을 보여주었습니다.
이번 협력은 Abera가 이전에 CEPI(전염병 대비 혁신 연합)로부터 받은 보조금으로 자금을 지원받고 있습니다. 이 파트너십은 Orexo의 분말 제형 전문성과 Abera의 30년 이상의 백신 개발 경험을 결합하여 AmorphOX의 확장성을 활용하기 위한 전략적 단계입니다.
Orexo AB (STO: ORX, OTCQX: ORXOY) a établi une collaboration avec Abera Bioscience pour développer des vaccins en poudre nasale en utilisant la technologie AmorphOX® d'Orexo. Le partenariat vise à développer des vaccins muqueux, en se concentrant initialement sur le candidat vaccin contre la grippe d'Abera. La technologie AmorphOX a montré un potentiel pour améliorer la stabilité et l'efficacité de divers ingrédients actifs, allant de petites molécules à de plus grandes biomolécules comme les vaccins.
La collaboration est financée par des subventions que Abera a précédemment reçues, principalement de CEPI (Coalition for Epidemic Preparedness Innovation). Ce partenariat représente une étape stratégique pour tirer parti de la scalabilité d'AmorphOX, combinant l'expertise d'Orexo en matière de formulation en poudre avec plus de 30 ans d'expérience dans le développement de vaccins d'Abera.
Orexo AB (STO: ORX, OTCQX: ORXOY) ist eine Zusammenarbeit mit Abera Bioscience eingegangen, um Nasenpulverimpfstoffe unter Verwendung von Orexos AmorphOX® Technologie zu entwickeln. Das Ziel dieser Partnerschaft ist es, mukosale Impfstoffe zu entwickeln, wobei der Fokus zunächst auf dem Influenza-Impfstoffkandidaten von Abera liegt. Die AmorphOX-Technologie hat das Potenzial gezeigt, die Stabilität und Wirksamkeit verschiedener aktiver Inhaltsstoffe zu verbessern, von kleinen Molekülen bis hin zu größeren Biomolekülen wie Impfstoffen.
Die Zusammenarbeit wird durch zuvor erhaltene Fördermittel von Abera finanziert, hauptsächlich von CEPI (Coalition for Epidemic Preparedness Innovation). Die Partnerschaft stellt einen strategischen Schritt dar, um die Skalierbarkeit von AmorphOX zu nutzen und Orexos Fachwissen in der Pulverformulierung mit über 30 Jahren Erfahrung in der Impfstoffentwicklung von Abera zu kombinieren.
- Strategic expansion of AmorphOX technology into vaccine delivery market
- Project funding secured through existing CEPI grants
- Technology demonstrates versatility across multiple drug types
- None.
- The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology AmorphOX®.
- Abera is a developer of mucosal vaccines and has several preclinical vaccine candidates based on Abera's innovative vaccine platform.
- The AmorphOX technology has the potential to improve the stability and efficacy of Abera's vaccine candidates.
UPPSALA,
As a next strategic step to leverage the scalability of AmorphOX, Orexo has entered into a collaboration with Abera Bioscience ('Abera'), a platform and vaccine developer with over 30 years of research in the medical, molecular and microbiological fields. The aim of the collaboration is to develop mucosal vaccines based on Abera's innovative and patented vaccine platform.
As a first step, the aim is to develop powder-based intranasal vaccine candidates, focusing on Abera's influenza vaccine candidate. An intranasal influenza vaccine has the potential to easily and effectively help reduce the spread of infections and prevent disease, which could play an important role in a potential future pandemic.
"Influenza is a family of viruses that could mutate and cause the next pandemic, but seasonal influenza is already a major problem where vaccines are often not effective enough. Orexo has an impressive knowledge and technology for powder formulations of medicines that perfectly complements our expertise in vaccine development. Their innovative technology, AmorphOX, has shown to improve the properties of a wide range of different active ingredients. There is therefore great potential in this area, and we will be able to take many important development steps in the coming year," says Maria Alriksson, CEO of Abera Bioscience.
The collaboration is funded by Abera through various previously received grants, mainly from CEPI (the Coalition for Epidemic Preparedness Innovation).
Robert Rönn, SVP and Head of R&D at Orexo, says: "Abera has an innovative and promising vaccine platform for the development of mucosal vaccines, as confirmed by their recent funding from CEPI. The collaboration is fully in line with our strategic development of the AmorphOX® platform and through collaborations we can showcase the potential and value of our technology. We look forward to working with Abera, where our experience and technologies are highly complementary."
For more information:
Orexo AB (publ.)
Nikolaj Sørensen, President and CEO
Lena Wange, IR & Communications Director
Tel: +46 (0)18 780 88 00
E-mail: ir@orexo.com
About Orexo
Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2023 amounted to
For more information on Orexo, visit www.orexo.com. Follow Orexo on X, LinkedIn, and YouTube.
About AmorphOX
Orexo's proprietary drug delivery platform, AmorphOX, is a powder made up of particles which are built using a unique combination of a drug, carrier materials and, optionally, other ingredients. The particles are presented as an amorphous composite of the various ingredients providing for excellent chemical and physical stability, as well as rapid dissolution. The technology works for a broad scope of active ingredients and has been validated in several human clinical studies showing rapid and extensive drug exposure.
About Abera
Abera Bioscience AB is a Swedish vaccine and biotechnology company founded in 2012, originating from molecular biology research at Vrije Universiteit Amsterdam and
About BERA™
Abera's BERA™ vaccine platform is based on bacterial particles known as OMVs (Outer Membrane Vesicles), which are decorated with a large number of disease-specific antigens. Vaccines based on the BERA platform can be administered as nasal sprays and create protection in both mucosal membranes and systemically in the body, aiming to protect against both disease and transmission. The platform technology enables the rapid development of new vaccine candidates as antigens can be replaced in a plug-and-play manner.
The information was submitted for publication at 8.00 am CET on December 17, 2024.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Orexo enters into collaboration with Abera to develop nasal powder vaccines_Publ 17 dec 2024 |
View original content:https://www.prnewswire.com/news-releases/orexo-enters-into-collaboration-with-abera-to-develop-nasal-powder-vaccines-based-on-the-amorphox-technology-302333481.html
SOURCE Orexo
FAQ
What is the purpose of Orexo's collaboration with Abera Bioscience for ORXOY investors?
How is the Orexo-Abera vaccine development collaboration being funded?
What is the initial focus of the Orexo-Abera vaccine development partnership?
What advantages does AmorphOX technology offer for vaccine development?
How does the Abera collaboration align with Orexo's (ORXOY) business strategy?
